CTRI/2024/02/063096
Not yet recruiting
未知
Metabolic response by FDG PET-CT and its correlation with pathological response and genomic profile in patients of Non-Small Cell Lung Cancer (NSCLC) receiving neoadjuvant chemoimmunotherapy - NI
AIIMS New Delhi0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: C348- Malignant neoplasm of overlappingsites of bronchus and lung
- Sponsor
- AIIMS New Delhi
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age 18\-75 years Pathological diagnosis of NSCLC in Stage 2B or 3A . Being considered for neoadjuvant chemotherapy followed by surgery after discussion in MDT. Complete surgical removal should be deemed achievable including surgical fitness. ECOG (Eastern Cooperative Oncology Group) performance score 0to1\. Adequate organ functions and marrow functions as described below
- •A. Serum creatinine less than equal to 1\.5 mg or creatinine clearance more than equal 50 ml/min. B. Serum Bilirubin less than 1\.5 UNL, ASTor ALT less than 3 UNL C. Hb more than 10\.0 gmdl, Platelet counts more than 100 x10 9 L, absolute neutrophil count more than 1\.5 X10 9L Able to understand the PIS (patient information sheet and give informed consent)
Exclusion Criteria
- •ECOG performance score more or equal to 2 .Harboring EGFR mutations, ALK and ROS1 rearrangements.Prior exposure to immune checkpoint inhibitors. Pre\-existing autoimmune condition requiring systemic immunosuppression including steroids (more than 10 mg Prednisolone equivalent).
- •Acquired immunosuppression (HIV, systemic immunosuppression)
- •.Hematopoietic or organ transplant recipient. History of any other malignancy in past or synchronous malignancy.Pregnant and lactating mothers. Willing to afford or have access to immunotherapy outside study.Patients with any medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or compromise the patient’s ability to participate in this study.Uncontrolled diabetes mellitus with fasting plasma glucose persistently above 200 mgdl which could compromise the patient’s ability to undergo FDG PET\-CT scan.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
FDG (Fluorodeoxyglucose) Findings After COVID-19 VaccinationVaccine ReactionOncologyNCT05270967Kocaeli University129
Recruiting
Phase 3
Role of PET/CT scan to look for response of chemo and radiotherapy in esophageal cancer before surgeryPurpose of this study is to see whether PET/CT scan is useful to assess whether chemo and radiotherapy are working and the cancer is reducing or notHealth Condition 1: null- Carcinoma esophagus patients undergoing neoadjuvant chemoradiotherapyCTRI/2014/01/004276All India Institute of Medical Sciences New Delhi50
Completed
Not Applicable
Study of Metabolic Connectivity in Drug-resistant Temporal EpilepsyEpilepsyNCT05455047Central Hospital, Nancy, France90
Active, not recruiting
Not Applicable
PET/CT Scan as a Tool to Rationalize the Treatment of Patients With Advanced ColoRectal Cancer Undergoing First-line Medical TreatmentColorectal Cancer Stage IVNCT02618850National Cancer Institute, Naples260
Active, not recruiting
Not Applicable
PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First ChemotherapyNon-small Cell Lung Cancer MetastaticNon-small Cell Lung Cancer Stage IIIBNCT02035683National Cancer Institute, Naples220